Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme

Hannah Majeski, Kirti Chahal, Angela Pasis, Casey Carlson, Qiao Liu, Arvind Shakya, Akinori Okano, Shenlin Huang, Aparajita Hoskote Chourasia* and Leah Fung * (*co-last authors)

Biotheryx, Inc., San Diego, CA

Abstract # 3111

BACKGROUND



CDK4 and CDK6 are kinases which regulate cell cycle progression through the phosphorylation of retinoblastoma protein (Rb) which releases the transcription factor E2F, driving the expression of cell cycle promoting genes. CDK4/6 are clinically validated targets in HR+/HER2- breast cancer, with multiple CDK4/6 inhibitors (CDK4/6i) approved for use in this indication, but resistance remains an issue with >20% of patients exhibiting intrinsic resistance and up to 70% of patients developing acquired resistance within 3 years.[1] Many resistance mechanisms converge on the upregulation of CDK6.[2-5] To address this we sought to generate CDK4/6 bifunctional degraders.

METHODS

- PRODEGY platform was utilized to develop a series of Cereblon (CRBN) mediated CDK4/6 bifunctional degraders including development candidate BTX-9341.
- Knockout cell lines were generated by nucleofection of Cas9-gRNA complexes.
- Target degradation was analyzed by immunoblots of protein lysates from cells treated with BTX-9341 for 6 hours or as indicated.
- Phosphorylated Rb was analyzed by in cell western after 24 hours of treatment or by immunoblot where indicated.
- E2F target gene expressed was analyzed by qPCR and immunoblot.
- Cell proliferation was measured by CellTiter-Glo 2.0 assay (Promega) after a 10-day colony formation assay. 10-Day CFA was utilized for synergy assays as well.
- Vehicle, CDK4/6 inhibitor(s), and BTX-9341 were dosed orally in BALB/c nude mice xenograft subcutaneous and intracranial models.

RESULTS

- BTX-9341 is a potent, CRBN dependent degrader of CDK4 and CDK6 in multiple breast cancer cell lines.
- Kinome profiling indicates BTX-9341 is more selective than the CDK4/6i palbociclib at 100 nM, and proteomics indicates minimal off-target degradation.
- BTX-9341 inhibits downstream signaling, including:
- Rb phosphorylation in breast cancer cells with pRb IC_{50}s below 50 nM.
- Downregulation of E2F target genes at the mRNA and protein level which is sustained over a period of 72 hours while CDK4/6 inhibitors show recovery of target gene expression.
- Inhibition of proliferation, with colony formation assay IC_{50}s in the low nanomolar range.
- BTX-9341 exhibits synergy with the selective estrogen receptor degraders (SERDs) fulvestrant and camizestrant in a colony formation assay.
- BTX-9341 retains potency in a CDK4/6i resistant cell line and exhibits enhanced synergy with fulvestrant and camizestrant in this resistant cell line as compared to palbociclib with fulvestrant.
- BTX-9341 exhibits good tumor exposure when dosed orally, and induces a dose-dependent reduction in CDK4, CDK6, and pRb levels in MCF7 xenograft tumors. In this model, BTX-9341 exhibits dose dependent tumor growth inhibition and tumor regression at higher doses that was well correlated with CDK4, CDK6 and pRb downregulation.
- BTX-9341 also inhibits tumor growth in several other HR+/HER2- xenograft models.
- BTX-9341 inhibited tumor growth in both a subcutaneous and an intracranial GBM xenograft model.

BTX-9341 degrades CDK4 and CDK6 with minimal off-target binding or degradation

Degradation of CDK4 and CDK6 at 6 hours of treatment in MDA-MB-231 cells



Degradation of CDK4 and CDK6 at 6 hours of treatment HR+ breast cancer cell lines



Representative Simple Western™ blots for two HR+ cells lines on the left. Quantified immunoblots for all tested HR+ cell lines on the right. CAMA1 cells do not express CDK6. BT-474 cell line is HER2+, all other cell lines are HER2-.

Kinome selectivity profiling of BTX-9341



Kinome S(35) score: the fraction of kinases with less than 35% of control at 100nM among the 468 kinases tested with the KINOMEscan™ platform from Eurofins.

Compound	Kinome S(35) score @100nM
BTX-9341	0.01
Palbociclib	0.027

Proteomics of BTX-9341 treated MDA-MB-231 cells

TMT mass spectrometry performed on samples generated in triplicate from MDA-MB-231 cells treated with 100 nM of BTX-9341 or DMSO for 6 hours. Volcano plot indicating the fold change comparing BTX-9341 treated and DMSO treated cells. CDK4 and CDK6 are labeled as some of the few proteins which were significantly altered after BTX-9341 treatment.

Compound	CDK6 Kd
BTX-9341	31 nM
Palbociclib	5.1 nM

BTX-9341 inhibits RB phosphorylation, cell proliferation and downstream signaling

BTX-9341 inhibits cell proliferation



BTX-9341 activity is dependent on Cereblon

Degradation of CDK4/CDK6 at 6 hours in MDA-MB-231 control and CRBN knockout cells



BTX-9341 inhibits Rb phosphorylation



Inhibition of proliferation in MDA-MB-231 control and CRBN knockout cells



BTX-9341 downregulates E2F target genes at the mRNA and protein level



BTX-9341 inhibits E2F target gene mRNA expression in T47D cells. Suppression of gene expression is sustained through 72 hours, while recovery of gene expression is seen starting at 48 hours after palbociclib treatment



BTX-9341 inhibits E2F target gene expression at the protein level in T47D cells. Suppression of protein expression is deepened at 72 hours with BTX-9341 treatment, while recovery of protein expression is seen with some concentrations of palbociclib and PF-07220060

BTX-9341 exhibits strong synergy with SERDs fulvestrant and camizestrant in HR+ T47D cells andT47D cells resistant to palbociclib

BTX-9341 exhibits synergy with fulvestrant and camizestrant in T47D cells

BTX-9341 and camizestrant synergy



	HSA	Loewe
Synergy Score	5.941	2.459
Most synergistic area	14.138	12.592

BTX-9341 and fulvestrant synergy



	HSA	Loewe
Synergy Score	8.158	3.189
Most synergistic area	15.475	11.022

BTX-9341 inhibits cell proliferation, Rb phosphorylation and synergizes with fulvestrant and camizestrant in a palbociclib resistant cell line



Inhibition of Rb phosphorylation over time measured by immunoblot after treatment of T47D control and palbociclib resistant cells with BTX-9341 or palbociclib.

BTX-9341 and camizestrant synergy



	HSA	Loewe
Synergy Score	8.236	7.342
Most synergistic area	18.885	18.272

BTX-9341 and fulvestrant synergy



	HSA	Loewe
Synergy Score	10.96	12.49
Most synergistic area	21.62	24.07

Palbociclib and fulvestrant synergy



	HSA	Loewe
Synergy Score	3.26	3.40
Most synergistic area	6.46	8.11

BTX-9341 induces tumor regression in breast cancer xenograft models

BTX-9341 degrades CDK4, and CDK6, AND inhibits pRb in MCF7subcutaneous tumors



BTX-9341 exhibits dose-dependent target degradation of CDK4 and CDK6 which correlates with a dose-dependent decrease in phosphorylated Rb relative to total Rb that is rapid and sustained.



BTX-9341 exhibits dose-dependent target degradation of CDK4 and CDK6 which correlates with a dose-dependent decrease in phosphorylated RB relative to total RB in and MCF7 xenograft efficacy model. Decreases in pRB more significant than CDK4/6i at dose levels higher than 25mpk.

BTX-9341 induces tumor regression in multiple HR+/HER2- breast caner xenograft models



BTX-9341 exhibits dose-dependent tumor growth inhibition in an MCF7 xenograft model. BTX-9341 dosed at 25mpk BID, 50 mpk QD and 100 mpk QD all cause tumor regression in this model.





BTX-9341 induces tumor regression in an MCF7 xenograft model at 25mpk BID, 50mpk QD and 100 mpk QD in a 5 day on, 2 day off dosing schedule and a 21 day on 7 day off dosing schedule.



BTX-9341 exhibits dose-dependent tumor growth inhibition in two HR+/HER2- xenograft models ZR-75-1 and T47D. Tumor regression is seen at all doses of BTX-9341 tested.

BTX-9341 inhibits tumor growth in GBM xenograft models

U-118 subcutaneous xenograft GBM model





BTX-9341 induces potent tumor growth inhibition in a U-118 subcutaneous GBM model. U118 cells are MGMT-positive, and begin to show tumor regrowth with Temozolomide treatment, while mice treated with all doses of BTX-9341 continue to show tumor growth inhibition, even after treatment withdrawal.

U-87 MG intracranial xenograft GBM model



BTX-9341 induces potent tumor growth inhibition with BTX-9341 is superior to CDK4/6 inhibitors and leads to increased survival.



CONCLUSIONS

These preclinical data show that BTX-9341 promotes specific, CRBN dependent degradation of CDK4 and CDK6 in multiple breast cancer cell lines. This degradation leads to a deeper and more sustained inhibition of phospho-Rb, E2F target gene expression and cell proliferation when compared to CDK4/6i. BTX-9341 was efficacious in a palbociclib-resistant cell line. BTX-9341 displayed synergy with SERDs that was maintained in a palbociclib resistant cell line, indicating that a degrader approach in combination with a SERD may work well in patients who are resistant to CDK4/6 inhibitors. BTX-9341 exhibited potent tumor growth inhibition in multiple HR+/HER2- breast cancer and multiple GBM xenograft models. Considering these properties, we are beginning a phase 1 clinical trial with BTX-9341 in HR+/HER2- breast cancer patients who have progressed after CDK4/6i therapy.

REFERENCES

1. Scheidemann, E.R., et al. *Int J Mol Sci* **22**, 12292 (2021).
2. Álvarez-Fernández, M., et al. *Cancer Cell* **37**, 514-529 (2020).
3. Li, Z., et al. *Cancer Cell* **34**, 893-904 (2018).
4. Li, Q., et al. *Cancer Discovery* **12**, 356-371 (2022).
5. Razavi, P., et al. *Cancer Cell* **34**, 427-438 (2018).

biotheryx

http://www.biotheryx.com